A novel case of neonatal severe hyperparathyroidism successfully treated with a type II calcimimetic drug

We report a boy with hypercalcemia due to neonatal severe hyperparathyroidism (NSHPT) caused by a compound heterozygous mutation in the calcium sensing receptor (CaSR) managed successfully on a type II calcimimetic drug. The hypercalcemia was temporarily treated by hyperhydration, bisphosphonate and...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	T.L. Leunbach, A.T. Hansen, M. Madsen, R. Cipliene, P.S. Christensen, A.J. Schou
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2021-06-01
Saila:	Bone Reports
Gaiak:	Neonatal severe hyperparathyroidism Symptomatic hypercalcemia Compound heterozygosity Type II calcimimetics
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S2352187221000164
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!